Vernalis and C4x Discovery to pursue modulators of hard-to-drug target in inflammatory disease
April 9, 2024
Vernalis (R&D) Ltd., a subsidiary of Hitgen Inc., and C4x Discovery Holdings plc have entered into a collaboration to identify modulators of an undisclosed, hard-to-drug, high-value target involved in inflammatory disease.
